Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Payables (2021 - 2025)

Historic Payables for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $1.1 million.

  • InMed Pharmaceuticals' Payables fell 2183.16% to $1.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 million, marking a year-over-year decrease of 2183.16%. This contributed to the annual value of $1.4 million for FY2025, which is 1509.83% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Payables stood at $1.1 million for Q4 2025, which was down 2183.16% from $1.1 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Payables registered a high of $3.4 million during Q4 2021, and its lowest value of $1.0 million during Q3 2024.
  • Over the past 5 years, InMed Pharmaceuticals' median Payables value was $1.5 million (recorded in 2023), while the average stood at $1.7 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Payables skyrocketed by 2314.41% in 2022 and then tumbled by 5570.84% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Payables (Quarter) stood at $3.4 million in 2021, then plummeted by 42.34% to $2.0 million in 2022, then crashed by 34.65% to $1.3 million in 2023, then increased by 6.49% to $1.4 million in 2024, then fell by 21.83% to $1.1 million in 2025.
  • Its Payables was $1.1 million in Q4 2025, compared to $1.1 million in Q3 2025 and $1.4 million in Q2 2025.